The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The evolving role of AI in myeloid malignancies
In this video, Jowan Al-Nusair, MD, Marshall University, Huntington, WV, briefly discusses the evolving role of artificial intelligence (AI) in myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). She highlights the potential of machine learning to enhance diagnosis, prognostication, treatment prediction, and research. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
